Skip to main content
Transparency
Twitter
YouTube
Linkedin
cat
esp
eng
ABOUT US
RESEARCH
COVID-19
INNOVATION AND TRANSFER
LEARNING
LIVING LAB HEALTH
NEWS
COLLABORATE
Cerca
who are you?
Who are you?
I'm an
Investigator
I'm
Community
I'm an
Educator
or Student
I'm a
Collaborator
I'm a
Journalist
IrsiCaixa’s scientific activity search engine
Search by
Filter by strategic line
All lines
Immunopathogenesis
Microbiome
Other diseases
Prevention, eradication and functional cure
New treatments and resistance to antiretrovirals
Filter by research group
All the groups
Retrovirology and Clinical Studies (GREC)
Cell Virology and Immunology (VIC)
Microbial Genomics
Virus-Host Interactions (ViHIT)
Host Genetics and Cellular Immunity
HIV and HCV Genetic and Phenotypic Variability
Tissue Virology (VITI)
Viral Immune Evasion and Vaccines (VIRIEVAC)
Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan)
Pathogen immunity, signaling and therapeutic applications (PISTA)
Translational Research in Immunology and Aging (TRIA)
From Date
Date
To Date
Date
Search
Filter by category
Strategic lines
Research groups
Researchers
Projects
Publications
Clinical research
Events
Publication
Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF
Publication
Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells
Publication
Evolution of HIV-1 Protease over 14 Years: Fitness Loss or Robustness Gain?
Publication
The origin of AIDS
Publication
Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome
Publication
New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors
Publication
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32
Publication
Susceptibility of Human Lymphoid Tissue Cultured ex vivo to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection
Publication
Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors
Publication
2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies
« first
‹ previous
…
42
43
44
45
46
47
48
49
50
…
next ›
last »
IrsiCaixa: RT @FAQSTV3: -- El president del Parlament, Roger Torrent; els doctors Bonaventura Clotet i Oriol Mitjà, i el sociòleg portuguès Boaventura…
IrsiCaixa: -- Ha arribat el dia! El Dr Bonaventura Clotet, director d'IrsiCaixa, ha rebut avui la primera dosi de la vacuna. ---- #JoEmVacuno contra la COVID-19, per tothom qui no pot fer-ho i per poder tornar a abraçar-nos ben aviat! ---- Seguim
IrsiCaixa: ♀ Gracias a @NoMoreMatildas, una iniciativa de @twitamit_es, por visibilizar el #EfectoMatilda, dando a conocer logros de científicas eclipsados a lo largo de la historia e inspirando a futuras #MujeresEnCiencia. ------ Si quieres conoce
IrsiCaixa: RT @FeedbackToday: ¡Buenos días y feliz 2021! Ya estamos de vuelta con más entrevistas. Hoy os ofrecemos una entrevista con el Dr. Bonavent…
IrsiCaixa: --️ "S'ha d'insistir en què cal seguir estudiant, desenvolupant nous models i mantenint les mesures de precaució" Bonaventura Clotet, director d'IrsiCaixa, ara mateix a @elmonarac1 -- https://t.co/BmIN9M2lLI
IrsiCaixa: RT @elmonarac1: -- Tertúlia entre experts en la lluita contra el coronavirus --Bonaventura Clotet --@ToniTrilla --Magda Campins --@prieto_alham…
IrsiCaixa: RT @CCO_InfDis: Don't miss this #MedicalMinute presentation as Dr. Roger Paredes @RutgerWalls reviews safety and efficacy data on #COVIDー19…
IrsiCaixa: ------ Do not miss this webinar organised by the IrsiCaixa Living Lab for Health! Check it out here ---- https://t.co/LR1gT4j0Ub
IrsiCaixa: -- @diariARA | @jblanco_vic, d'IrsiCaixa, remarca la importància d'una vacunació global en el menor temps possible -- "Cal parlar de vacunes en plural. L'ideal és que hi hagi diferents empreses fabricant-ne i que cada va
IrsiCaixa: ------ L'Agència Europea de Medicaments aprova la #vacuna de #Moderna. L'investigador d'#IrsiCaixa @jblanco_vic remarca que la composició de les vacunes Pfizer-BioNTech i Moderna és molt similar i que "no ens hem de preo
Subscribe to our newsletter
I accept the sending of communications about IrsiCaixa activities, promotions and scientific and educational innovations
*
es
ca
en
Back to Top